(Q38959070)

8 September 2017

Efficacy trial of malaria vaccine SPf66 in Gambian infants (English)

1 reference

8 September 2017

0 references

1 reference

1 reference

6

1 reference

8 September 2017

U D'Alessandro

1

1 reference

8 September 2017

A Leach

2

1 reference

8 September 2017

C J Drakeley

3

1 reference

8 September 2017

S Bennett

4

1 reference

8 September 2017

B O Olaleye

5

1 reference

8 September 2017

M Jawara

7

1 reference

8 September 2017

P Langerock

8

1 reference

8 September 2017

M O George

9

1 reference

8 September 2017

G A Targett

10

1 reference

8 September 2017

language of work or name

English

0 references

publication date

1 August 1995

1 reference

8 September 2017

1 reference

8 September 2017

346

1 reference

8 September 2017

462-467

1 reference

8 September 2017

8973

1 reference

Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Induction of protective immunity against experimental infection with malaria using synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 1. A review of the epidemiology and control of malaria in The Gambia, west Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Malaria prevalence is inversely related to vector density in The Gambia, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Identification of Mosquito Blood Meals by Enzyme-Linked Immunosorbent Assay *

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Field evaluation of enzyme-linked immunosorbent assays for Plasmodium falciparum and Plasmodium vivax sporozoites in mosquitoes (Diptera: Culicidae) from Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Comparison of two simple methods for determining malaria parasite density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

What is clinical malaria? Finding case definitions for field research in highly endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Attributable fraction estimates and case definitions for malaria in endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Lack of an association between acute gastroenteritis, acute respiratory infections and malaria in young Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

The immune recognition of malaria antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

A specific T-cell receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

Merozoite surface antigen-I of plasmodium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2991321-1

7 January 2021

10.1016/S0140-6736(95)91321-1

Identifiers

DOI

1 reference

8 September 2017

1 reference